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CytotoxicityGlioblastoma multiforme (GBM) is the most malignant form of brain tumor and is associated with
resistance to conventional therapy and poor patient survival. Prostate apoptosis response (Par)-4, a
tumor suppressor, is expressed as both an intracellular and secretory/extracellular protein. Though
secretory Par-4 induces apoptosis in cancer cells, its potential in drug-resistant tumors remains to
be fully explored. Multicellular spheroids (MCS) of cancer cells often acquire multi-drug resistance
and serve as ideal experimental models. We investigated the role of Par-4 in Tamoxifen (TAM)-
induced cell death in MCS of human cell lines and primary cultures of GBM tumors. TCGA and REM-
BRANT data analysis revealed that low levels of Par-4 correlated with low survival period
(21.85 ± 19.30 days) in GBM but not in astrocytomas (59.13 ± 47.26 days) and oligodendrogliomas
(58.04 ± 59.80 days) suggesting low PAWR expression as a predictive risk factor in GBM. Consistently,
MCS of human cell lines and primary cultures displayed low Par-4 expression, high level of chemo-
resistance genes and were resistant to TAM-induced cytotoxicity. In monolayer cells, TAM-induced
cytotoxicity was associated with enhanced expression of Par-4 and was alleviated by silencing of
Par-4 using speciﬁc siRNA. TAM effectively induced secretory Par-4 in conditioned medium (CM)
of cells cultured as monolayer but not in MCS. Moreover, MCS were rendered sensitive to TAM-
induced cell death by exposure to conditioned medium (CM)-containing Par-4 (derived from
TAM-treated monolayer cells). Also TAM reduced the expression of Akt and PKCf in GBM cells
cultured as monolayer but not in MCS. Importantly, combination of TAM with inhibitors to PI3K
inhibitor (LY294002) or PKCf resulted in secretion of Par-4 and cell death in MCS. Since membrane
GRP78 is overexpressed in most cancer cells but not normal cells, and secretory Par-4 induces apop-
tosis by binding to membrane GRP78, secretory Par-4 is an attractive candidate for potentially over-
coming therapy-resistance not only in malignant glioma but in broad spectrum of cancers.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Glioblastoma multiforme (GBM) is the most common primary
tumor of the CNS in adults and accounts for more than 50% of
malignant gliomas [30]. Despite the advancement in therapies
including surgical resection and improved chemo- and radiother-
apy, the prognosis is poor with median survival period of
14.6 month [1,54,60]. Based on the gene expression proﬁle and
molecular signatures, GBM has been classiﬁed into four subtypes
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standing the biology of aggressive gliomas is very important to
design better and effective strategies for treatment and to improve
survival for GBM patients. However, one of the major hurdles in
performing studies to identify targets and signaling pathways in
aggressive tumors is limitation of experimental models. Much of
the data accumulated over decades from preclinical studies have
relied upon conventional 2D cell cultures using cancer cell lines.
Though these studies have contributed towards enhancing our
knowledge of gliomas, the model suffers from inherent disadvan-
tage of not reﬂecting the structure and biology of in vivo tumors
[7,42]. Multicellular spheroids (MCS) in contrast to 2D-monolayers
are 3D structures and mimic many of features like the architecture,
cell–cell interaction, oxygen and nutrient transport and conditions
of in vivo tumors including the necrotic core [20,27]. Numerous
studies have reported that spheroids display multi-drug resistance
and are also resistant to radiotherapy compared to cells cultured as
monolayers [15, 17]. MCS therefore serve as attractive model for a
wide range of studies including as drug delivery, toxicity, and
metabolism [31,34,39].
Prostate apoptosis response (Par)-4, a tumor suppressor was
ﬁrst identiﬁed in rat prostate cancer cells undergoing apoptosis
in response to apoptotic stimuli [50]. Par-4 is a pro-apoptotic
protein of approximately 38 kDa, encoded by PAWR gene (PKC
apoptosis WT1 regulator) [38] and expressed ubiquitously in
normal and cancer cells. Consistent with its tumor-suppressive
activity, Par-4 is silenced or down regulated transcriptionally or
post-transcriptionally in various types of cancers [14,40,45].
Several studies have documented the association of low level of
Par-4 with poor prognosis in cancers of prostate [45,49,2] endome-
trial [40], renal [14], pancreas [2], and breast [41]. Par-4 has been
shown to activate apoptosis through intrinsic and extrinsic
pathways [4,10]. Upregulation or induction of Par-4 by apoptotic
stimuli such as tumor necrosis factor alpha (TNFa), TRAIL [6] and
Fas [11] induce cell death in cancer cells. Other studies showed
that overexpression of Par-4 enhances the activity of anticancer
drugs such as 5-ﬂuorouracil [59,28] and induces radio-sensitivity
[12]. While the intracellular role of Par-4 is established and the
mechanisms well studied, recent studies have demonstrated that
secretory or extracellular Par-4 induces apoptosis in cancer cells
[9,46]. However, the potential of secretory Par-4 in drug-resistant
tumors remains to be fully explored. We previously reported that
upregulation of intracellular Par-4 and secretion of Par-4 were cru-
cial for tamoxifen (TAM)-induced apoptosis in human glioma stem
cells [25]. In the present study, we investigated the role of intracel-
lular and secretory Par-4 in drug-induced apoptosis in human GBM
cells using multicellular spheroids (MCS) as a model. We show that
MCS derived from glioma cells are resistant to TAM-induced cyto-
toxicity and Par-4 secreted by TAM-treated glioma monolayers
rendered MCS sensitive to TAM-induced cell death. Our ﬁndings
also suggest the involvement of Akt and PKCf in induction of secre-
tory Par-4 and sensitization of MCS to TAM-mediated cytotoxicity.
2. Materials and methods
2.1. Ethics statement
The study was approved by the Ethics Committee of NCCS
(Pune, India).
2.2. Chemicals
Tamoxifen, temozolomide, PKCf pseudosubstrate inhibitory
peptide and all ﬁne chemicals were procured from Sigma–Aldrich
(India) and PI3K inhibitor LY294002 was purchased from
Calbiochem.2.3. Cell culture
Human Glioma cell lines; LN-18 and LN-229 were maintained
in Dulbecco’s modiﬁed eagle’s medium (DMEM) with 4 mM L-glu-
tamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and
supplemented with 5% heat-inactivated fetal calf serum (Gibco
BRL, Carlsbad, CA, USA). HNGC-2 cells were cultured in DMEM
medium supplemented with 5% fetal bovine serum (FBS,Gibco).
Antibiotics (100 IU/ml penicillin and 100 lg/ml streptomycin
(Sigma, USA) were added to the culture media. Cultures were
maintained in 5% CO2 humidiﬁed incubator at 37 C and cells
grown for 24 h were used for experiments.
2.4. Development of primary cultures from tumor samples
GBM tumor samples were provided by D.Y. Patil Medical Col-
lege and Inamdar Hospital (Pune). Grading of tumors was done
according to WHO criteria by pathologist. Tumor tissues were
ﬁnely chopped in DMEM/Ham’s F12 medium (1:1) containing anti-
biotics and enzymatically digested with zymefree and accutase
(Sigma, Saint Louis, MO) for 2 h and passed through a cell strainer
(100 lm; BD, Germany) to obtain single cell suspension. Cells were
then washed and plated in DMEM/Ham’s F12 (1:1) medium with
antibiotics and 10% FCS in petridishes. Primary cultures once
established were maintained in complete DMEM medium supple-
mented with 10% FCS. In this study, primary cultures derived from
GBM tumor-G1 was used and experiments were conducted with
cells in passages between15 and 30.
2.5. Generation of multi-cellular spheroids (MCS)
The liquid overlay technique described earlier with slight
modiﬁcation was used to generate spheroids. Petridishes or plates
were coated with 0.8% agarose in DMEM and allowed to solidify for
30 min at room temperature. Spheroids were generated by inocu-
lating 6  105 cells per 60 mM petridishes, or 104 cells/well of 96
well plates in DMEM supplemented with 5% fetal calf serum. The
spheroids were treated with drugs and processed for MTT assay
or Western blotting.
2.6. MTT assay
The effect of tamoxifen and temozolomide on cell viability was
assessed in glioma cell lines and primary cultures (G1) by MTT 3-
(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide
assay. Cells were treated for 24 h with drugs or with DMSO (vehicle
control). MTT (5 mg/ml) was added and formazan crystals formed
were dissolved in 10% SDS along with 0.01 N HCl. The absorbance
was measured at 570 nm with reference to 640 nm using micro-
plate reader (Molecular Devices, SPECTRA max 250, USA) and per-
cent viable cells was calculated considering values in control as
100%. Vehicle control cells showed cell viability >95%.
2.7. Annexin V and PI staining
Cells were treated with tamoxifen for 12 h and apoptosis was
determined using Annexin-V apoptosis detection kit (BD Pharmin-
gen, USA) according to the manufacturer’s protocol. Data was
acquired with ﬂow cytometry (FACS CantoII, Becton–Dickinson)
and analysis was done using Cell Quest Pro software
(Becton–Dickinson).
2.8. Mitochondrial membrane potential (MMP)
The mitochondrial membrane potential was measured using
Mitocapture Apoptosis Detection Kit (Oncogene Research). Cells
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Flowcytometric analysis for disruption of mitochondrial
membrane potential was done using FL-1 parameter in BD–FACS
Canto II. Increase in green ﬂuorescence depicts breakdown in mito-
chondrial membrane potential.
2.9. Generation of reactive oxygen species (ROS)
Dihydroethidium (DHE) is a lipophilic cell-permeable dye that
can undergo oxidation to ethidium bromide or a similar product
in the presence of superoxide, and, to a lesser extent, hydrogen
peroxide and hydroxyl radicals. DHE ﬂuorescence was quantitated
by ﬂowcytometry analysis on FL2-channel.
2.10. Confocal laser scanning microscopy
Control and tamoxifen treated cells were ﬁxed with 3.7%
paraformaldehyde for 10 min and permeabilized with 0.2% triton
X-100 for 5 min. Cells were washed with PBS three times at each
interval. After blocking for 1 h in 3% BSA, cells were incubated with
antibody to Par-4 (Santa Cruz Biotechnology, USA) for 2 h followed
by goat anti-rabbit Cy3 labeled antibody or phalloidin for actin,
(Molecular Probes, Invitrogen, USA) for 1 h at room temperature.
DAPI was used to stain nucleus. Images were acquired using confo-
cal laser scanning microscope (Carl Zeiss or Leica, Germany).
2.11. Western blotting
Control and treated cells were lysed using RIPA lysis buffer
(120 mM NaCl, 1.0% Triton X-100, 20 mM Tris–HCl, pH 7.5, 100%
glycerol, 2 mM EDTA and protease inhibitor cocktail, Roche,
Germany). Total protein (30 lg) was electrophoresed on 10%
SDS–polyacrylamide gels and blotted onto PVDF membrane
(Millipore, Bedford, MA, USA). After blocking with 5% BSA at room
temperature, the blots were probed with one of these antibodies:
Par-4 (Cell signaling technologies, Santa Cruz Biotechnology,
USA), PARP (Santa Cruz Biotechnology), GRP78 (Abcam, Cambridge,
England), Akt, PKCf, actin (Molecular probes, Invitrogen, USA),
pAkt-ser 473, or pPKC f (Santa Cruz Biotechnology) overnight at
4 C. The secondary antibodies were horseradish peroxidase-conju-
gated goat anti-rabbit IgG and goat-anti-mouse IgG (Bio-Rad, USA).
The immunoreactive bands were visualized by chemiluminescence
using Super Signal West Femto Maximum Sensitivity Substrate
(Pierce, USA). GAPDH and actin were used to normalize levels of
proteins detected.
For secretion of Par-4, HNGC-2, LN-18 and G1 cells were
exposed to tamoxifen for 24 h and supernatants were collected
and concentration (20-fold) was achieved using 30 kDa cut-off
ﬁlters (Millipore, USA).
2.12. Real time PCR
RNA was isolated using TRIzol reagent (Invitrogen, USA) and
reverse-transcribed into cDNA (Promega, Madison, WI) according
to the manufacturer’s instructions. Quantitative real time PCR
was performed using SYBR Premix Ex Taq™ II (Takara, Japan)
in Realplex Real-Time Thermal Cycler (Eppendorf). PCR reactions
were performed in duplicates and program consisted of initial
activation at 95 C for 2 min followed by 40 cycles of denatur-
ation at 95 C for 15 s and primer annealing at 60 C for 45 s.
Melting curve analysis was used to determine the speciﬁc PCR
products. All primers used for Real-Time PCR analysis were
synthesized by Integrated DNA Technologies, India. GAPDH or
18s ribosomal RNA was used as an internal control. List of the
primers is included in Table 1 of Supplementary data. The
changes in the threshold cycle (CT) values were calculated bythe equation: DCT ¼ CTðtargetÞ  CTðendogenous controlÞ and fold differ-
ence was calculated as 2DðDCT Þ.
2.13. Transfections
LN-18 and LN-229 cells were cultured in 96 well, 6 well plates
or on coverslips to 70% cell conﬂuency. Cells were transfected
with lipofectamine 2000 (Invitrogen Carlsbad, USA) and ON-TAR-
GET plus SMART pool, human PAWR siRNA or non-targeting
siRNA (Dharmacon, Inc., USA). After 48 h, the cells were treated
with tamoxifen and assessed for cell viability by MTT assay or
processed for analysis of Par-4 levels by Western blotting and
immunoﬂuorescence.
2.14. Immunohistochemical staining
The expression of PAR-4 was examined in brain glioblastoma
tissue array (US Biomax, Inc). The samples included 40 samples
in duplicates of GBM of different grades and normal brain tissue
as control. Antigen retrieval was done by using citrate buffer, pH
6.0 by microwave method. The sections were cooled and washed
with PBS before incubating in 3% aqueous hydrogen peroxide for
15 min to quench endogenous peroxidase activity. Nonspeciﬁc
binding was blocked by incubation with serum for 30 min at room
temperature. The sections were stained for Par-4 speciﬁc antibody
(Sigma, USA) for 2 h at RT. The antigen–antibody complexes were
detected by Dako kit (EnVision™ G|2 Doublestain System, Rabbit/
Mouse (DAB+/Permanent Red Code K5361). Diaminobenzidine
was used as a chromogen and sections were counterstained with
hematoxylin. The sections were dehydrated, and mounted with a
glass coverslip and DPX used as mounting media. Negative controls
included sets processed similarly in the absence of Par-4 antibod-
ies. The slides were viewed by expert pathologists and scored
based on intensity of staining, negative staining (zero), low (+)
medium (++) and high (+++).
2.15. RNA isolation and microarray analysis
LN-18 cells were cultured as monolayers or spheroids for 24 h
and processed for RNA isolation. Samples in duplicates from two
different passages were processed for microarray analysis. RNA
was extracted using TRIzol reagent (Invitrogen, Carlsbad, USA) as
per manufacturer’s instructions and RNA was quantiﬁed using
Nanodrop VR spectrophotometer (NanoDrop Technologies, Wil-
mington, DE). Sample ampliﬁcation was performed with 200 ng
of total RNA using Agilent’s Quick Amp Labeling Kit One Color to
generate complementary RNA (cRNA) for oligo microarrays. cRNA
was processed for microarray analysis on a Whole Human Genome
Oligonucleotide Microarray (G4112A, 41,000 genes; Agilent
Technologies, Santa Clara, CA) according to the manufacturer’s
instructions. Microarray experiments were performed at Geno-
typic Technology, (Bengaluru, India).
Microarray data analysis-Raw data was normalized and
processed with GeneSpring.
GX10.0.2 software (Agilent Technologies). Genes with a fold
change >1.5 and a p-value < 0.05 were considered as differentially
expressed. Data analysis was done at Bionivid Technology,
(Bengaluru, India). For data visualization, unsupervised hierarchi-
cal clustering was performed with the Pearson metric and average
linkage method.
2.16. TCGA and REMBRANT data acquisition and processing
The Cancer Genome Atlas (TCGA) has the largest comprehensive
data for different types of cancers. The TCGA project comprises
multimodal data of glioma cases that includes Low grade gliomas
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classical, mesenchymal, proneural and neural and normal samples.
The data is available from the TCGA website (https://tcga-data.nci.-
nih.gov/tcga/). REMBRANDT is portal for data exclusively from
brain tumors including GBM (228 cases) astrocytomas (148) oligo-
dendrogliomas (67) and normal cases (21). The dataset was
searched for GBM cases for level 3 gene expression based on the
Agilent microarrays (Human gene U133A). The expression value
of PAWR gene for each case was collected and cases were segre-
gated as High (expression value P2), Low (expression value
62) and Intermediate value (expression value between ±1.2
and ±2.0) tumor samples. Survival period was calculated in days/
months from the date of diagnosis to the time of death. From TCGA,
we collected data for gene expression of LGG (27), GBM (97) and
normal samples (10) and selected PAWR for analysis. The mean
and SD values were calculated and analyzed for signiﬁcance
between groups and subtypes. Survival data of glioma cases from
(Rembrandt data) was stratiﬁed into high, low and intermediate
levels of expression of PAWR and KM plot for Highest intensity
probe (204004_at) for samples were plotted. Comparison for sur-
vival probability between groups was done.
2.17. Statistical analysis
The data is represented as mean ± standard deviation. Indepen-
dent t-test was used to calculate the difference of the data between
two groups in viability assay. Chi-square test was used to evaluate
the difference in the expression of Par-4 analyzed by immunohis-
tochemistry. Kaplan–Meier estimates (log-rank test) were used to
study if a variable was associated with the survival of glioma
patients. p-values < 0.05 were considered signiﬁcant.
3. Results
3.1. PAWR is differentially expressed in low and high grade gliomas
The expression of PAWR was signiﬁcantly lower (p < 0.05) in
LGG compared to normal samples (Fig. 1A–a). GBM samples
displayed a high degree of variation in PAWR expression and the
level was not signiﬁcantly different compared to normal group
(Fig. 1A–b). Interestingly, analysis of GBM samples classiﬁed into
subtypes [58] revealed that PAWR was upregulated (p < 0.036) in
mesenchymal group and downregulated (p < 0.01) in classical with
respect to normal, thus indicating a differential expression among
GBM tumors (Fig. 1A–c). To examine the signiﬁcance of Par-4 in
survival, REMBRANDT data for gliomas was downloaded and sam-
ples were stratiﬁed for expression of PAWR into upregulated,
downregulated and intermediate groups. Kaplan–Meier survival
plots were drawn based on the expression levels of PAWR and ana-
lyzed by log-rank test. The survival period is signiﬁcantly lower in
cases with low level of PAWR (13.16 ± 9.00) compared to cases
with upregulated (22.65 ± 24.82) and intermediate
(20.17 ± 18,20) level (Fig. 1B). We further analyzed the data for
association of PAWR and survival period in different types of glio-
mas. Samples with low expression (tumor samples with expression
value 6 (mean (normal samples)  SD (normal samples) of PAWR
were sorted within astrocytoma, oligodendroglioma and GBM
groups. As depicted in Fig. 1C, low PAWR expression correlated
with low survival period (21.85 ± 19.30) in GBM but not in astrocy-
tomas (59.13 ± 47.26) and oligodendrogliomas (58.04 ± 59.80) sug-
gesting that low PAWR is a predictive risk factor in GBM.
To analyze the expression of Par-4 protein in gliomas, immuno-
histochemical staining was done in tissue sections of array
comprising grade III astrocytomas, GBM and normal brain samples.
The samples were scored based on the intensity of staining. Nor-
mal brain tissues expressed detectable levels of Par-4, scored aslow (+ or ++) in 5/7 samples (Fig. 2B). GBM showed variation with
samples showing no staining (negative), moderate or high
intensity of Par-4 (Fig. 2A). The expression levels of Par-4 was
not signiﬁcantly different between normal and GBM. The variation
may be attributed to samples of different subtypes of GBM
included in the array. These results are in line with the TCGA data
in GBM.
3.2. Upregulation of genes associated with chemoresistance in MCS
model of human GBM cells
Multicellular spheroids were generated from human glioma cell
lines – LN-18, LN-229 and primary cultures-G1. It was interesting
to note that even with equivalent cell number the spheroids were
morphologically different. LN-229 cells formed very compact and
large spheroids while LN-18 cells formed loose spheroids of differ-
ent sizes. The primary culture-G1 formed small spheroids (Fig. 3A).
Gene proﬁling analysis of LN-18 cells revealed differential expres-
sion of genes associated in MCS compared and cells in monolayers
(Fig. 3B). Functional annotation of differentially expressed tran-
scripts using Gene Ontology (GO) revealed that the number of
genes most signiﬁcantly altered (FCP 2 and p 6 0.05) were in
the categories of cell adhesion, cell junction and regulation of cell
proliferation. Other groups included genes associated with cyto-
skeleton and actin organization (Fig. 3C). Cell–cell interactions
resulting in cytoskeletal reorganization activate multiple signal
transduction pathways that directly inﬂuence cell survival, growth
and differentiation [21]. Multidrug resistant phenotype is reported
to correlate with increased expression of genes associated with
chemoresistance [57]. We analyzed the microarray data for altera-
tions in the expression of chemoresistance genes in MCS. As shown
in Fig. 3D genes associated with chemoresistance that were
expressed at very low level in monolayers were upregulated in
MCS. The functions of each of these chemoresistance genes are
depicted in Supplementary data – Table S2. To validate the micro-
array data, transcript levels of the chemoresistance genes with
inclusion of additional genes were measured in LN-18, LN-229 cell
lines and G1 primary culture by quantitative real-time PCR (qRT-
PCR). As shown in Fig. 4A, most of the chemoresistance genes ana-
lyzed were upregulated in MCS compared to cells grown as mono-
layer cells. The genes upregulated were similar in LN-229 and G1
cells while LN-18 cells showed upregulation of 7 additional genes.
A comparison of the gene expression levels from microarray data
and q-PCR is shown in table (Fig. 4B). Most importantly, nine genes
that were overexpressed were common in the MCS of all three cell
cultures. Fig. 4C indicating the relevance of upregulation of genes
related to chemoresistance in MCS.
3.3. MCS are resistant to TAM-induced cell death
To assess the response of monolayers and MCS to TAM and TMZ,
we performed MTT viability assay in LN-18, LN-229 and G1 cells.
Dose response curves showed that the cell lines were more sensi-
tive to TAM than TMZ. We also observed that MCS of the cell lines
and G1 were resistant even at 15 lg/ml of TAM (Fig. 5 and Supple-
mentary Fig. 1). These preliminary data suggested that MCS from
glioma cell lines and from primary cultures of GBM tumor are
resistant to TAM-induced cytotoxicity.
3.4. MCS display low level of Par-4 compared to cells in monolayer
Par-4 is a pro-apoptotic protein and is upregulated in response
to many apoptosis stimuli [47,53]. Based on our preliminary
observations that MCS display high levels of chemoresistance
genes and are resistant to TAM-induced cell death, it was of inter-
est to examine the expression of Par-4 in the two culture models.
Fig. 1. Expression of PAWR gene and survival analysis in gliomas (A) Box-plots depict comparison of PAWR expression between (a) Low grade gliomas (LGG) and normal
brain tissue; (b) GBM and normal brain tissue; (c) subtypes of GBM and normal brain tissue. The data is derived from TCGA analysis on Agilent platform. Rembrandt data base
comprising cases of GBM (228), astrocytoma (148) and oligodendroglioma (67) was downloaded and Kaplan–Meier estimates (log-rank test) were made (B) Survival graphs
in GBM cases with low, intermediate and high level of PAWR gene (C) Comparison of survival probability in GBM, astrocytoma and oligodendroglioma cases with low
expression of PAWR gene. Bars represent mean values ± SD, ⁄p < 0.05 difference was between normal vs tumor groups.
Fig. 2. Expression of Par-4 in tissue samples of Gliomas and normal brain by immunohistochemical staining. (A) The panel shows negative control and one normal sample
(above), negative control and three GBM samples showing different intensities of Par-4 expression (below). (B) The table summarizes the number and level of expression of
Par-4 in GBM, normal and astrocytoma groups.
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showed a remarkable reduction in Par-4 transcript compared to
monolayer and the effect was more evident in G1 cells. Whole cell
lysates of LN-18 cells cultured as MCS showed down regulation of
Par-4 and was not signiﬁcantly different in MCS cultured for 24, 48
and 72 h (Fig. 6B). Further results with Western blotting and
immunoﬂuorescence staining in LN-229, G1 and LN-18 cells
conﬁrmed reduced Par-4 expression in MCS compared to cells
grown as monolayers (Fig. 6C and D).3.5. TAM upregulates Par-4 expression and induces cell death in cells
grown as monolayers but not in MCS
Further experiments were performed to examine the effect of
TAM on the expression of Par-4 in the two culture models. Par-4
level increased at 3 and 6 h in monolayers and MCS and gradually
decreased with time, however the increase was more robust in
monolayers (Fig. 7A). In G1 primary cells, increased expression of
Par-4 was observed with TAM at 24 h in monolayers but there
Fig. 3. Differential gene expression patterns between monolayers (ML) and multicellular spheroids (MCS). (A) Human glioma cell lines-LN-18, LN-229 and G1 primary culture
was grown as ML and MCS for 24 h. The images show the difference in size and morphology of MCS formed in the 3 cell types. (B) Hierarchal clustering proﬁle of genes
expressed (analyzed by microarray data) in ML and MCS derived from LN-18 cell line. The datasets represent two separate RNA samples for each of the culture models. (C)
Graphical representation of selectively enriched gene ontology categories (p value 6 0.05) in MCS analyzed with Gene spring software. The number of genes differentially
regulated in the respective processes is mentioned in parentheses. (D) The graph depicts fold changes in expression of chemoresistance genes in ML and MCS of two data sets.
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Par-4 expression in the two cultures systems. To assess the effect
on apoptosis, the cell lysates were monitored for PARP cleavage.
As shown in Fig. 7C, cleaved PARP was detected in LN-18 and G1
cells grown as monolayers but not in MCS. To examine the involve-
ment of Par-4 in apoptosis, LN-18 and LN-229 cells transfected
with Par-4 speciﬁc siRNA and control siRNA were exposed to
TAM for 24 h and cell viability was measured by MTT assay. As
depicted in Supplementary ﬁgures – Figs. 2 and 3, TAM induced
apoptosis as quantitated by Annexin-V/PI staining and breakdown
in mitochondrial membrane potential in these cell lines. Also TAM
(10 lg) increased the necrotic population in LN-18 cells. Staining of
cells with Dihydroethidium (DHE) revealed that 24.51% cells were
positive for ROS compared to control cells (4.97%, Supplementary
Fig. 3) suggesting that generation of ROS might have contributed
to necrosis in cells exposed to TAM. Par-4 silenced cells showed
higher cell viability in TAM-treated cells compared with control-
non-target siRNA suggesting the role of Par-4 in TAM-induced
apoptosis.
3.6. TAM induces secretory Par-4 and downregulates levels of Akt and
PKCf in monolayers but not in MCS
We have previously demonstrated the role of secretory Par-4 in
TAM-induced apoptosis in glioma stem cell line-HNGC-2 [25]. To
address the question to what might be the factors that contribute
to sensitivity/resistance in monolayers and MCS, we chose to
analyze the conditioned medium (CM) of G1 cells treated with
TAM. Interestingly, signiﬁcant level of Par-4 was detected in
supernatants of cells cultured as monolayer but not in MCS(Fig. 8A). Based on these data, we speculated whether addition of
exogenous Par-4 would render MCS sensitive to TAM-induced
apoptosis. For this purpose, we treated MCS of G1 cells with TAM
in the presence of CM derived from HNGC-2 cells treated with
TAM and assessed for cell viability. We observed that MCS exposed
to TAM showed reduced viability in the presence of conditioned
medium (CM) containing secretory Par-4 but not control CM. Also,
treatment with CM-containing secretory Par-4, alone did not affect
cell viability (Fig. 8B).
To further conﬁrm the involvement of secretory Par-4, CM of
HNGC-2 cells exposed to TAM was incubated with antibody to
Par-4 and the mixture was added to G1 cells in combination with
TAM. As shown in Fig. 8C, a signiﬁcant recovery was observed with
Par-4 antibody thatwas concentrationdependent but notwith irrel-
evant (p35) or control antibody. Similar results were obtained in
LN-18 cells (Supplementary Fig. 4). These ﬁndings suggest that
secretory Par-4 and TAM-mediated intracellular signaling are both
essential for inducing apoptosis. Extracellular Par-4 is reported to
induce apoptosis by binding to the stress response protein, glu-
cose-regulated protein-78 (GRP78). We found that MCS of G1 cells
express lower level of GRP78 compared tomonolayers and TAM did
not affect the expression of GRP78 in both the models (Fig. 8D).
PKCf is a binding partner of Par-4 and affects its proapoptotic
function via Akt regulation [26]. Treatment of TAM in LN-18 and
LN-229 cells resulted in reduced levels of PKCf and Akt in lysates
of monolayers but not in MCS (Fig. 9A). To test whether Akt con-
tributed to resistance in MCS, we assessed cell viability in response
to TAM in combination with inhibitors to PI3K (LY294002) and
PKCf (PKCf pseudosubstrate inhibitory peptide). As shown in
Fig. 9B, TAM-induced cell death was signiﬁcantly enhanced in
Fig. 4. Regulation of genes related to chemoresistance genes in MCS (A) Transcript levels of chemoresistance genes in glioma cell lines and primary culture (G1) measured by
quantitative real-time PCR (qRT-PCR). Y-axis represent fold change in MCS w.r.t ML. 18S rRNA or GAPDH was used as internal control. The data is mean ± of 3 independent
experiments for LN-18 and LN-229 cells. (B) The table shows the comparison of fold changes in the expression of chemoresistance genes generated by microarray analysis and
validated by qRT-PCR in LN-18 cell line. (C) The Venn diagram shows the genes upregulated in MCS among LN-18, LN-229 and G1 cultures.
Fig. 5. Dose dependent response of ML and MCS to tamoxifen and temozolomide. Graphs display dose dependent response of LN-18 and G1 grown as ML (blue) and MCS (red)
to tamoxifen and temozolomide. The effect was assessed by MTT assay. Cell viability of untreated control cells was considered as 100%. The data represents the mean ± SE
(n = 3). ⁄p < 0.01 difference between ML vs MCS.
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suggest the involvement of secretory Par-4 as well as intracellular
signaling involving Akt and PKCf in rendering MCS sensitive to
TAM-induced apoptosis.4. Discussion
A correlation between high levels of Par-4 and better survival
period has been reported in pancreatic cancers [2] and breast
Fig. 6. Gene and protein expression of Par-4 in ML and MCS. (A) The graph represents fold changes (logarithmic scale) of Par-4 gene quantiﬁed by qRT-PCR. Y-axis represents
fold change in MCS w.r.t ML (B) Protein levels of Par-4 measured by Western blotting in LN-18 cells cultured as ML and MCS for different time periods (C) Protein expression
of Par-4 in LN-229 and G1 cultures at 24 h by Western blot analysis. Actin was used as loading control. (D) Immunoﬂuorescence staining for Par-4 (red), actin (green) and
nucleus (blue) of LN-18 cells grown as ML (above) and MCS (below).
Fig. 7. MCS are resistant to TAM-induced apoptosis. (A) LN-18 cells were treated with TAM for different time periods and analyzed for Par-4 protein levels in ML (above) and
MCS (below). (B) Protein expression of Par-4 in G1 cells cultured as ML (above) and MCS (below). (C) ML and MCS derived from LN-18 and G1 were treated with TAM and cell
lysates were probed for PARP cleavage.
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reveals association of high PAWR expression with survival in
gliomas and suggests low PAWR level as a predictive risk factor
for GBM but not oligodendroglioma and astrocytoma groups. A
correlation between Par-4 expression and longer median survival
is reported in high-grade gliomas that are IDH1 wild type [35].
One of the factors associated with failure of preclinical studies
with anti-cancer agents has been the limitations in appropriateexperimental models. In this study, we used MCS generated from
human cell lines and primary cultures of GBM tumor to study
the role of Par-4 in drug resistance. Interestingly, though the
MCS differed in compactness and size in the cell lines and primary
cultures, 9 genes including ABC transporter family members and
Glutathione S-transferases (GSTs) that are involved in multi-drug
resistance [48] were common in the three cultures. Importantly,
MCS from the GBM cell lines and primary expressed low level of
Fig. 8. TAM induces secretory Par-4 in ML but not MCS. (A) G1 cells cultured as ML and MCS were treated with TAM for 24 h and supernatants were analyzed for secretory
Par-4 by Western blotting. The blots were stained with Ponceau and BSA was used as loading control (lower panel). (B) MCS of G1 were treated with combination of TAM and
secretory Par-4 derived from HNGC-2 cells exposed to TAM (described in Section 2). Supernatant of untreated HNGC-2 cells was used as control. Cell viability was assessed
after 24 h by MTT assay. (C) MCS of G1 cells were exposed to supernatant containing Par-4 that was pre incubated for 30 min with Par-4 antibody and cell viability was
assessed by MTT assay. Antibody to p35 and species speciﬁc IgG were used as internal control. (D) Expression of GRP78 in ML and MCS of TAM treated G1 cells was assessed
by Western blotting. GAPDH was used as loading control. ⁄p < 0.05 is difference in viability between cells-treated with TAM in combination with conditioned medium
containing Par-4 vs control supernatant (Fig. B) and in the presence of Par-4 antibody vs control antibody(Fig. C).
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chemoresistance genes. These data support the suitability of MCS
as a model to study the role of Par-4 in drug resistance.
Temozolomide, an alkylating agent is the front line drug for
treatment of GBM. It has been approved in the European Union
for the treatment of patients showing progression or recurrence
after standard therapy [18]. However, only 11% of the patients
remain progression free at 2 years of treatment with standard
therapy incorporating temozolomide [55]. Consistent with these
studies, we found monolayers as well as MCS of GBM cell lines
and primary cultures of GBM resistant to high doses of TMZ. Recent
studies suggest that high doses of tamoxifen can be beneﬁcial in
the treatment of gliomas [43,52]. TAM is being evaluated in clinical
trials for treatment of patients with malignant gliomas [24]. In our
in vitro culture models, in contrast to monolayers that were sensi-
tive, MCS were resistant to TAM-induced cell death, reafﬁrming
chemoresistance in MCS. Recent studies demonstrated that TAM
could signiﬁcantly reduce the MDR in a variety of human cancers
[36]. Par-4 level is enhanced in response to apoptotic stimuli by
anticancer agents in wide variety of cancer cells [59,53]. TAM
enhanced the expression of Par-4 in both cultures systems, though
more robustly in monolayer cells, apoptosis was induced in mono-
layers but not in MCS suggesting that upregulation of Par-4 is notsufﬁcient for inducing cell death. Recent studies have reported the
role of secretory Par-4 in apoptosis triggered by stimuli causing
endoplasmic reticulum stress in mammalian cells [10]. Our results
that TAM effectively enhanced the expression of intracellular but
not secretory Par-4 in MCS led us to hypothesize that secretory
Par-4 is essential for inducing cell death in MCS. In this context,
we observed that MCS was rendered sensitive to TAM-induced
apoptosis in the presence of conditioned medium that contained
Par-4 derived from HNGC-2 cells exposed to TAM. Furthermore,
the effect was abrogated on pretreatment of conditioned medium
with Par-4 speciﬁc antibody conﬁrming that the involvement of
secretory Par-4 in apoptosis stimulated by TAM. Collectively, these
ﬁndings suggested that extrinsic Par-4 is effective in enhancing
sensitivity of drug-resistant MCS to TAM-induced apoptosis.
The mechanism of induction of apoptosis by extracellular Par-4
involves interaction with cell surface GRP78 [51]. GRP78 is overex-
pressed in a variety of tumors and confers resistance to cytotoxic
therapy [62,23]. It is generally present as an endoplasmic reticu-
lum protein but its expression as a surface protein speciﬁcally in
tumor but not normal cells, makes it attractive as potential target
for anti-cancer therapy [63,29,33]. Previously, we reported that
extrinsic Par-4 induces apoptosis in human glioma stem cell line
HNGC-2 and the mechanism involved GRP78 [25]. In contrast to
Fig. 9. Role of Akt and PKCf in ML and MCS (A) LN-18 and LN-229 cells cultured as ML and MCS were treated with TAM for 24 h and cell lysates were analyzed for expression
of phosphorylated and total Akt and PKCf. Actin was used as loading control. (B) LN-18 MCS were treated with combination of TAM (10 lg/ml) and PKCf pseudosubstrate
inhibitor for 24 h and assessed for cell death. The data represents mean of two independent experiments. (C) Also LN-18 MCS were treated with combination of TAM (10 lg/
ml) and PI3K inhibitor (LY 294002) for 24 h and assessed for cell death. The data represents mean of two independent experiments. (D) Western blot represents the band of
secretory Par-4 when MCS of LN-18 treated with combination of TAM (12 lg/ml) and PI3K inhibitor (LY 294002) for 24 h. Lower panel shows BSA as loading control. ⁄p < 0.05
is difference in viability between cells-treated with TAM in combination with PKCf pseudosubstrate inhibitor/LY 294002.
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natant alone could not induce apoptosis. We speculate that Par-4
was ineffective due to low level of GRP 78 in MCS. Though we have
no direct evidence it is possible that low Par-4 expression led to
decreased GRP78 level as reported in trophoblastic cells [13]. The
expression of GRP78 is enhanced in response to a variety of ER
stress inducers such as glucose starvation or hypoxia [19,33].
Tamoxifen induce endoplasmic reticulum stress [3] and enhance
cytotoxicity of anti-cancer drug nelﬁnavir in breast cancer cells
[8]. On these lines, it is reasonable to infer that the combination
of TAM and secretory Par-4 is effective in inducing cytotoxicity
in MCS by different mechanisms. While TAM does not signiﬁcantly
enhance GRP78 in MCS, it induces endoplasmic reticulum stress
(as evidenced by caspase-12 activity-data not shown) and secre-
tory Par-4 interacts with surface GRP78 complementing the action
of TAM.
Further studies were directed towards identifying the possible
factors/molecules that may be crucial in enhancing TAM-induced
cytotoxicity. Activation of Akt and ERK42/44 signaling pathways
are important in drug resistance [5,37]. In pancreatic tumors,
Par-4 is known to act as a negative regulator of Akt activation via
PKC zeta [56,26]. PKCf is highly expressed in gliomas [61] and is
associated with Par-4 [16]. It is noteworthy that TAM reduced
the expression of Akt and PKCf in GBM cells cultured as monolayer
but not in MCS. Furthermore, inhibitors to PI3K/Akt or PKCf
enhanced TAM-induced cell death in MCS suggesting the
involvement of Akt-mediated signaling in the process. Another
study reported sensitization of glioma cells to tamoxifen-inducedapoptosis by Pl3-kinase inhibitor mediated via the GSK-3b/b-cate-
nin signaling pathway [32].
In conclusion, the present study has shown that secretory Par-4
sensitizes resistant glioma cells to TAM-induced apoptosis by
mechanism involving Akt and PKCf. Considering that little success
has been achieved with inhibitors targeting PI3K/Akt for cancer
therapy and TAM being evaluated in clinical trials for treatment
of malignant gliomas, our ﬁndings suggest that secretory Par-4
can be induced by a combination treatment of TAM and Akt inhib-
itors to effectively kill cancer cells. However, further studies are
warranted to identify the precise mechanism involved in secretion
of Par-4 mediated by PI3K/Akt pathways. Since secretory Par-4
functions by binding to membrane GRP78, which is overexpressed
in most cancer cells but not normal cells, secretory Par-4 is an
attractive candidate for potentially overcoming therapy-resistance
not only in malignant gliomas but in broad spectrum of cancers.
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